MT1-MMP

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Construction, Bioconjugate Chemistry, Thromboxane A2, MT1-MMP, Therapy, NASDAQ, Cancer research, CD137, Biotechnology, Drug development, Acceleration, BTC, Fine chemical, Bicycle, Bicycle

The article, titled Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides is available at the publications section of the Bicycle website at this link .

Key Points: 
  • The article, titled Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides is available at the publications section of the Bicycle website at this link .
  • Assessment of the suitability of this methodology to Bicycle phage screening is underway, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • Bicycles are formed through the reaction of three cysteine residues within a linear sequence with a trivalent, symmetrical small molecule scaffold.
  • Bicycles with high binding affinities to therapeutically important targets are discovered using a proprietary phage display technology.

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry

Retrieved on: 
Tuesday, July 12, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Technology, SEC, Clinical trial, Medicinal chemistry, Security (finance), Drug development, Biotechnology, U.S. Securities and Exchange Commission, Bicycle, Therapy, Thromboxane A2, BTC, Risk, Journal of Medicinal Chemistry, Journal, Cancer research, COVID-19, Private Securities Litigation Reform Act, Solubility, MT1-MMP, CD137, Forward-looking statement, NASDAQ, Fine chemical, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry.
  • We discovered BT7480 by using a series of novel Bicycles targeting CD137, which were conjugated to novel Bicycles targeting Nectin-4, said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts.

Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration

Retrieved on: 
Tuesday, July 12, 2022
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Technology, SEC, Security (finance), Drug development, Biotechnology, U.S. Securities and Exchange Commission, Program, Therapy, Thromboxane A2, BTC, Risk, Cancer research, Private Securities Litigation Reform Act, MT1-MMP, Forward-looking statement, Hoffmann-La Roche, Exercise, NASDAQ, CD137, Fine chemical, Pharmaceutical industry, Genentech, Bicycle, Bicycle

Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.

Key Points: 
  • Bicycle and Genentech are collaborating on the discovery and pre-clinical development of novel Bicycle-based immunotherapies against multiple targets.
  • Pursuant to the terms of the February 2020 agreement, Genentech was granted two collaboration expansion options, each of which gave Genentech the right to add one additional program to the collaboration in exchange for a $10 million payment to Bicycle.
  • In October 2021, Genentech exercised its first expansion option, and has now exercised its second expansion option, triggering an additional $10 million payment.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

Retrieved on: 
Wednesday, June 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Triple-negative breast cancer, Esophageal cancer, Large-cell lung carcinoma, Drug development, Company, Head, Biotechnology, Bicycle, Cancer research, CD137, Pharmacokinetics, Forward-looking statement, Spectrochimica Acta Part B, Security (finance), U.S. Securities and Exchange Commission, Therapy, ADC, Patient, Private Securities Litigation Reform Act, Risk, BTC, Phase, COVID-19, MT1-MMP, NASDAQ, SEC, Clinical trial, Neck, Safety, Fine chemical, Pharmaceutical industry, Thromboxane A2

The Phase I/II multi-center, open-label trial comprises two parts: Part A, dose escalation and Part B, dose expansion.

Key Points: 
  • The Phase I/II multi-center, open-label trial comprises two parts: Part A, dose escalation and Part B, dose expansion.
  • Up to 56 patients will be enrolled in the initial expansion cohorts, with the ability to further expand enrollment based on the results of the initial expansion cohorts.
  • Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts.

Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Drug development, Conference, Biotechnology, Bicycle, Cancer research, CD137, Webcast, Investor, Thromboxane A2, Therapy, BTC, MT1-MMP, NASDAQ, Fine chemical

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m.
  • A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycles website at www.bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Massachusetts.

Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Drug development, Annual general meeting, Private Securities Litigation Reform Act, Thromboxane A2, MT1-MMP, U.S. Securities and Exchange Commission, Poster, NASDAQ, Phase, Cancer research, CD137, Society, American Society of Clinical Oncology, BTC, Publication, Biotechnology, Forward-looking statement, ASCO, Therapy, SEC, Bicycle, Security (finance), Pharmaceutical industry

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Key Points: 
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry.
  • Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycles anticipated participation in the ASCO Annual Meeting.
  • Bicycle may not actually achieve the intentions disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Retrieved on: 
Monday, April 11, 2022
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Therapy, Drug development, Thromboxane A2, NASDAQ, Peripheral neuropathy, Investor, Forward-looking statement, RECIST, Â, ORR, MT1-MMP, Skin, Phase, SD, Biotechnology, SEC, Program, American Association, Conference, BTC, Incidence, Orange Riots, U.S. Securities and Exchange Commission, Bicycle, Squamous cell carcinoma, Association, Review, Hyperglycemia, Time, CD137, COVID-19, Cancer research, UC, MRCP, Toxic leukoencephalopathy, CR, Neoplasm, Annual report, Patient, DCR, Security (finance), Pharmaceutical industry, Medical imaging

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4.
  • The results were presented in an oral presentation on Sunday, April 10 at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, LA.
  • Since our initial BT8009 Phase I/II trial interim results last year, we are encouraged to see BT8009s promising profile endure over time.
  • As of March 7, 2022, thirty-seven patients have been dosed in the Phase I/II trial of BT8009.

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Company, Therapy, Drug development, Thromboxane A2, NASDAQ, Investor, MT1-MMP, Biotechnology, American Association, Conference, BTC, Webcast, Bicycle, Association, Review, CD137, Cancer research, Phase, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.
  • The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m.
  • Date/Time: Sunday, April 10, 2022 at 4:05 4:15 p.m. CT
    Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 6, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Drug development, Thromboxane A2, Therapy, NASDAQ, Investor, MT1-MMP, Biotechnology, Conference, BTC, Webcast, Bicycle, CD137, Cancer research, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 8:45 a.m.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 8:45 a.m.
  • A live webcast of the fireside chat will be accessible in the Investors and Media section of Bicycles Website at www.bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.
  • Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Publication, NASDAQ, MT1-MMP, CD137, Bicycle, Private Securities Litigation Reform Act, Drug development, Company, U.S. Securities and Exchange Commission, Therapy, Webcast, Cancer research, Annual report, Conference, Investor, Phase, Thromboxane A2, Dana–Farber Cancer Institute, BTC, Security (finance), American Association, Review, Ex vivo, Belfer Center for Science and International Affairs, COVID-19, Drug discovery, SEC, Association, Biotechnology, Forward-looking statement, Pharmaceutical industry, Vaccine

The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m.

Key Points: 
  • The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m.
  • Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m.
  • A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, bicycletherapeutics.com .
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.